ADC Therapeutics (ADCT) Other Non-Current Liabilities (2020 - 2026)

ADC Therapeutics has reported Other Non-Current Liabilities for 7 years, with the latest figure at $304.7 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 6.76% year-over-year to $304.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $304.7 million (down 6.76% YoY) and the FY2025 annual result came in at $322.5 million, up 0.76% from the prior year.
• Other Non-Current Liabilities fell to $304.7 million in Q1 2026 per ADCT's latest filing, from $322.5 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $340.2 million in Q3 2025 and troughed at $204.1 million in Q1 2022.
• A 5-year average of $285.3 million and a median of $305.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Other Non-Current Liabilities soared 46.61% in 2023, then declined 6.76% in 2026.
• Over 5 years, Other Non-Current Liabilities stood at $212.4 million in 2022, then soared by 42.96% to $303.6 million in 2023, then advanced by 5.44% to $320.1 million in 2024, then grew by 0.76% to $322.5 million in 2025, then slipped by 5.53% to $304.7 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $304.7 million, $322.5 million, and $340.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.